Michael Hennig studied Physics and Biochemistry and received the Ph.D. in structural biology at EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed two years postdoc work at the Biozentrum, University of Basel, Switzerland. He is author of more than 75 scientific peer reviewed paper and, since 2011, guest professor in structural biology at the University of Basel. From 1995 he worked 20 years in pharmaceutical industry at Roche, Basel, Switzerland in various positions and finally Global Head and Principle Leader of discovery technologies with responsibility for structure based drug discovery, protein science, assay development and HTS, corporate compound library, stem cell platform analytical methods. In 2015, he co-founded and is now CEO of leadXpro AG, a company dedicated to structure based drug discovery of membrane protein targets.
Structure based drug discovery, membrane protein structural biology, Synchrotron and Free Electron Laser, cryo-Electron Microscopy (EM), computational methods.